Review in Biomedica : revista del Instituto Nacional de Salud, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 4 institutions in 1 country.
Sonia Isabel Cuervo-MaldonadoFacultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia; Grupo de Infectología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia; Grupo de Investigación en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas (GREICAH), Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia. sicuervom@unal.edu.co.ORCID 0000-0001-5676-880X
José Camilo Álvarez-RodríguezGrupo de Infectología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia; Grupo de Investigación en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas (GREICAH), Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia. jcalvarezr@unal.edu.co.ORCID 0000-0001-7267-2461
Cristian Leonardo CubidesGrupo de Infectología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia; Grupo de Investigación en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas (GREICAH), Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia. clcubidesc@unal.edu.co.ORCID 0000-0001-8241-9179
Juan Camilo BarreraGrupo de Infectología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia; Grupo de Investigación en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas (GREICAH), Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia. juan.barrera@hun.edu.co.ORCID 0000-0003-0880-8496
Juan Diego Montañez-AbrilFacultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia; Grupo de Investigación en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas (GREICAH), Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia. jmontanez@unal.edu.co.
Erika Paola Vergara-VelaFacultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia. evergarav@unal.edu.co.ORCID 0000-0002-5906-9593
Carlos Humberto Saavedra-TrujilloFacultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia; Grupo de Enfermedades Infecciosas, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia. chsaavedrat@unal.edu.co.ORCID 0000-0003-0068-6631
María José López-MoraGrupo de Investigación en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas (GREICAH), Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia; Grupo de Infectología, Clínica de Marly, Bogotá, D.C., Colombi. mjlopezm@unal.edu.co.ORCID 0000-0001-9865-9097
Gloria Elena Mora-FigueroaGrupo de Infectología, Clínica de Marly, Bogotá, D.C., Colombia. elenamorafigueroa@gmail.com.ORCID 0000-0003-2717-9293
Adriana Celis-RamírezGrupo de Investigación Celular y Molecular de Microorganismos Patógenos (CeMoP), Universidad de los Andes, Bogotá, D.C., Colombia. acelis@uniandes.edu.co.ORCID 0000-0003-3057-1966
Rose Mary Jaramillo-CalleGrupo de Infectología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia. rjaramillo@cancer.gov.co.ORCID 0000-0003-4474-9390
Rafael Parra-MedinaGrupo de Investigación Patología Oncológica INC, Instituto Nacional de Cancerología, Bogotá, Colombia. rparram@cancer.gov.co.ORCID 0000-0002-8428-5837
Universidad Nacional de Colombia · COInstituto Nacional de Cancerología · COClínica Santa María · COUniversidad de Los Andes · CO
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
The fusariosis is an opportunistic mycosis caused by Fusarium spp. Its clinical presentation depends on the immunological status of the host, especially in patients with hematooncological diseases, whose manifestations vary from localized to invasive fungal infections. Skin or blood culture helps to guide combined antifungal treatment with amphotericin B and voriconazole.
Here, we present 13 cases in a period of eleven years of patients with cancer who developed disseminated fusariosis and their outcomes, together with a review of the related literature.
In this series of cases, mortality was 61.5 % (8/13), despite the use of the antifungal. Out of the 13 cases, 11 had hematological neoplasia and 2 solid neoplasia. The most determinant risk factor was profound neutropenia. Skin involvement and positive blood cultures in most cases allowed combined treatment prescription. Persistent febrile neutropenia associated with skin lesions, onychomycosis, nodules, or lung masses lead to suspicion of Fusarium spp. fungal invasive infection.
The aim of this series of cases is to remind healthcare professionals that oncological patients with deep and persistent febrile neutropenia can develop fusariosis.
Indexed as
Febrile NeutropeniaFusariosisNeoplasmsAntifungal AgentsHumansResearchAntifungal Agentsanfotericina Bespectrometría de masa por láser de matriz asistida de ionización desorciónfungemiaFusariumvoriconazol
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Fusariosis in cancer patients: 13 case series report and literature review · full record | OpenQuestion